On February 2, 2006, Chromos Molecular Systems Inc. announced that it had acquired Targeted Molecules Corporation, a privately held biotechnology company based in San Diego, CA. With the acquisition, Chromos gained two antibody product candidates for treatment of multiple sclerosis and acute thrombosis. Chromos was advised by a team from Fasken Martineau comprised of Iain Mant, Sonya Reiss and Deepak Gill.
Client Work
Chromos Molecular Systems acquires Targeted Molecules Corporation
Fasken
Reading Time
1 minute read
Subscribe
